Overview

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The BEYOND Follow-Up study will give patients who participated in the preceding BEYOND study the opportunity to continue treatment with the 500µg dose of interferon beta (IFNB) 1b and will further investigate the safety and tolerability profile of interferon beta 1b 500µg during longer-term treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Treatments:
Interferon beta-1b
Interferon-beta
Interferons